Sign in Subscribe
Cancer research

MRI-Based Radiomics Nomogram Predicts CD8+Tumor-Infiltrating Lymphocytes Levels in HER2-Positive Breast Cancer

Strategic Insights

— 1 min read

Researchers at Army Medical University have developed a radiomics nomogram that can predict the levels of CD8+ tumor-infiltrating lymphocytes (TILs) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This nomogram, based on radiomic features derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), has the potential to identify patients who may benefit from immunotherapy. The study, published in Frontiers in Oncology, involved 126 patients with pathologically confirmed HER2-positive breast cancer, who were randomly divided into training and validation cohorts. The radiomics nomogram model, based on radiomics features and clinical-imaging factors, achieved good performance in predicting CD8+ TILs, with an area under the curve (AUC) of 0.866 and 0.886 in the training and validation cohorts, respectively.

Key Takeaways:

  • The radiomics nomogram, developed by researchers at Army Medical University, can predict CD8+TILs levels in patients with HER2-positive breast cancer.
  • The nomogram is based on 126 patients with pathologically confirmed HER2-positive breast cancer, randomly divided into training (n=88) and validation (n=38) cohorts.
  • The radiomics nomogram model achieved an AUC of 0.866 and 0.886 in the training and validation cohorts, respectively, for predicting CD8+ TILs.
  • The nomogram significantly outperformed the clinical-imaging model (p < 0.05).
  • The radiomics nomogram has the potential to identify patients who may benefit from immunotherapy.

Statistics:

  • 126 patients with HER2-positive breast cancer were enrolled in the study.
  • The numbers of patients in the training and validation cohorts were n=88 and n=38, respectively.
  • The radiomics nomogram model achieved an AUC of 0.866 and 0.886 in the training and validation cohorts, respectively, for predicting CD8+ TILs.
  • The radiomics nomogram significantly outperformed the clinical-imaging model (p < 0.05).

Sources:

  • Frontiers in Oncology, "MRI-based radiomics nomogram for predicting CD8-positive tumor-infiltrating lymphocytes levels in HER2-positive breast cancer," 2025, 15. (https://doi-org.sdpl.idm.oclc.org/10.3389/fonc.2025.1612631)
  • NewsRx, "Research from Army Medical University in Breast Cancer Provides New Insights (MRI-based radiomics nomogram for predicting CD8-positive tumor-infiltrating lymphocytes levels in HER2-positive breast cancer)," Immunotherapy Weekly, October 29, 2025, p 778.

Read more